CXCR3 and ovarian carcinoma: In an in vitro assay, it was found that the production of malignant ascites in ovarian cancer could be inhibited by anti-CXCR3 monoclonal antibodies, thereby inhibiting tumor cell metastasis, suggesting that CXCR3 could be an essential indicator for evaluating the prognosis of ovarian cancer patients.